

To: Sunny Balwani[sbalwani@theranos.com]; Brooke Buchanan[bbuchanan@theranos.com]; Heather King[hking@theranos.com]; Elizabeth Holmes[eholmes@theranos.com]; Donald Tschirhart[dtschirhart@theranos.com]
From: Kingshuk Das[/O=THERANOS ORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=KINGSHUK DASE2B]
Sent: Thur 3/31/2016 10:38:48 PM (UTC)
Subject: Re: statement

That works for me--it's accurate, in my opinion

From: Sunny Balwani
Sent: Thursday, March 31, 2016 3:36 PM
To: Brooke Buchanan; Heather King; Elizabeth Holmes; Kingshuk Das; Donald Tschirhart
Subject: statement

King. WSJ has asked if they can use the following statement we provided to them. can you please let me know if this seems reasonable? thanks.

“CMS surveys evaluate lab practices. The deficiencies cited refer to how certain Theranos technologies were used and not to the fundamental integrity of the technologies themselves. The company’s proprietary technologies have already been cleared for testing HSV-1 by the FDA. Separately, the majority of the CMS deficiencies were not related to Theranos proprietary technologies.”